LBRX

LB Pharmaceuticals Inc Common Stock NASDAQ Listed Sep 11, 2025

Healthcare ·Biotechnology ·US · lbpharma.us

$31.93

Mkt Cap $915.6M

52w Low $13.36 92.3% of range 52w High $33.47

50d MA $26.72 200d MA $21.20

P/E (TTM) -31.4x

EV/EBITDA -10.5x

P/B 2.6x

Debt/Equity 0.0x

ROE -8.4%

P/FCF -16.0x

RSI (14) —

ATR (14) —

Beta -0.18

50d MA $26.72

200d MA $21.20

Avg Volume 260.2K

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

CIK (SEC)

1691082

Phone

212 605 0300

One Pennsylvania Plaza · New York, NY 10119 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 26, 2026	AMC	-0.45	-0.45	+0.0%	24.53	+1.7%	-2.8%	-2.5%	+6.1%	+0.6%	+3.5%	—
Nov 6, 2025	AMC	-0.57	-0.61	-7.0%	15.51	+0.3%	-1.0%	-4.8%	+9.4%	-5.6%	-1.2%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 27	H.C. Wainwright	Initiates	Buy	$45	$30.73	$30.94	+0.7%	+3.5%	-1.4%	-2.5%	+3.7%	-0.9%
Mar 27	Stifel	Maintains	Buy → Buy	—	$24.53	$24.94	+1.7%	-2.8%	-2.5%	+6.1%	+0.6%	+3.5%
Dec 11	Stifel	Maintains	Buy → Buy	—	$21.36	$21.69	+1.5%	-5.3%	-5.4%	+3.8%	-0.2%	-3.9%

Data updated apr 25, 2026 6:36pm · Source: massive.com